Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2021 at "AntiCancer Research"
DOI: 10.21873/anticanres.15395
Abstract: Background/Aim: This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma… read more here.
Keywords: plus paclitaxel; weekly cetuximab; recurrent metastatic; oral squamous ... See more keywords
Weekly Cetuximab and Paclitaxel for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "In Vivo"
DOI: 10.21873/invivo.12084
Abstract: Background/Aim: Head and neck cancers account for 8% of all cancer cases worldwide. However, identifying the optimal treatment for recurrent or metastatic head and neck cancer (R/MHNSCC) has been challenging. The aim of this study… read more here.
Keywords: head; recurrent metastatic; weekly cetuximab; metastatic head ... See more keywords